Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2025 Vol. 3 > No. 3 > 100152
Next Article Previous Article
COMMENTARY   Open Access     Cite

Balancing cGVHD and GVL with Axatilimab: A macrophage-targeted strategy in allogeneic transplantation

  • 1.

    State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

  • 2.

    Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

  • 3.

    Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China

  • 4.

    Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China

  • 5.

    These authors contributed equally

More Information
The Innovation Medicine  3(3),  https://doi.org/10.59717/j.xinn-med.2025.100152  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Wolff D., Cutler C., Lee S. J., et al. (2024). Axatilimab in recurrent or refractory chronic graft-versus-host disease. N. Engl. J. Med. 391:1002−1014. DOI:10.1056/NEJMoa2401537

    View in Article CrossRef Google Scholar

    [2] Alexander K. A., Flynn R., Lineburg K. E., et al. (2014). CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J. Clin. Invest. 124:4266−4280. DOI:10.1172/jci75935

    View in Article CrossRef Google Scholar

    [3] Kitko C. L., Arora M., DeFilipp Z., et al. (2023). Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: Results of a phase I/II study. J. Clin. Oncol. 41:1864−1875. DOI:10.1200/jco.22.00958

    View in Article CrossRef Google Scholar

    [4] Boiko J. R., Ensbey K. S., Waltner O. G., et al. (2025). Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease. Blood 145:2214−2228. DOI:10.1182/blood.2024025337

    View in Article CrossRef Google Scholar

    [5] DeFilipp Z., Kim H. T., Knight L. W., et al. (2025). Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood 145:2312−2316. DOI:10.1182/blood.2024028005

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Lu H., Wang Y., Mo X., et al. (2025). Balancing cGVHD and GVL with Axatilimab: A macrophage-targeted strategy in allogeneic transplantation. The Innovation Medicine 3:100152. https://doi.org/10.59717/j.xinn-med.2025.100152
    Lu H., Wang Y., Mo X., et al. (2025). Balancing cGVHD and GVL with Axatilimab: A macrophage-targeted strategy in allogeneic transplantation. The Innovation Medicine 3:100152. https://doi.org/10.59717/j.xinn-med.2025.100152

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(3896) PDF downloads(1161)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.